Outcome of Board Meeting held on Jun 26, 2026

Wanbury Pharma Limited has approved the incorporation of a subsidiary in India with an estimated capital outlay of approximately 4,10,000. The company has also appointed M/s. Ernst & Young LLP as the Internal Auditor for the financial year 2026-2027. All investments related to the subsidiary will be disclosed to stock exchanges as per regulatory requirements.

Reported results are the point at which prior management commitments become checkable against audited or reviewed numbers.

• Margin trend against the prior period
• Cash from operations against reported profit
• Whether prior guidance is reaffirmed
• We will continue our API growth journey in FY27 with recent launches and a strong pipeline. (management committed by FY27)
• A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. (management committed by Q4 FY26)